Boston Scientific (NYSE:BSX) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Boston Scientific (NYSE:BSX) released its earnings results on Wednesday. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01, FiscalAI reports. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific updated its Q2 2026 guidance to 0.820-0.840 EPS and its FY 2026 guidance to 3.340-3.410 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Q1 results were strong: organic sales grew 9.4% and adjusted EPS was $0.80 (up 6%), with an adjusted operating margin of 28%, at the high end of guidance.
• Management lowered 2026 guidance, now targeting 6.5%–8% organic growth (Q2 guide 5%–7%) and adjusted EPS of $3.34–$3.41, citing unanticipated headwinds in key franchises.
• CHAMPION‑AF delivered favorable results (all primary and secondary endpoints), which the company expects will support label updates, guideline/NCD considerations, and long‑term expansion of the WATCHMAN population.
• Near‑term pressure in EP and Urology: EP saw greater-than-expected share erosion amid intensifying competition and PolarX/ACURATE discontinuations affected EMEA, while Urology underperformed in stone management and sacral neuromodulation.
• Capital moves and M&A: Boston Scientific expects the Penumbra deal to close in H2 2026 (pending approvals) and added $4B to its repurchase program, planning to repurchase about $2B of shares in Q2, signaling active capital return and tuck‑in M&A focus.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $64.95 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $96.53 billion, a PE ratio of 33.48, a P/E/G ratio of 0.92 and a beta of 0.78. The firm has a fifty day simple moving average of $68.87 and a 200 day simple moving average of $86.16. Boston Scientific has a twelve month low of $59.38 and a twelve month high of $109.50.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat: Boston Scientific reported Q1 revenue of $5.20B (+11.6% YoY) and adjusted EPS $0.80, modestly beating consensus — a demonstration of continued top‑line strength that supports medium‑term growth expectations. Press Release
• Positive Sentiment: Strong profit rebound: GAAP net income and operating performance improved sharply in Q1 (net income roughly doubled year‑over‑year), which underpins margins and ROE metrics cited in reports. WSJ: Net Grows Sharply
• Positive Sentiment: Options/institutional activity: Elevated call‑option buying and unusual options volume ahead of/from the print suggests speculative bullish positioning that can amplify intraday upside. Options Activity
• Neutral Sentiment: Analysts still largely positive: Several firms kept Buy/Outperform ratings (Jefferies, Barclays, etc.) even as they trimmed price targets — that maintains long‑term support while trimming near‑term upside. Jefferies Coverage
• Neutral Sentiment: Multiple PT cuts but ratings retained: Firms (Truist, Baird, Needham, Barclays, Jefferies) trimmed targets — reduces headline upside but signals continued analyst conviction. Benzinga: PT Changes
• Negative Sentiment: Guidance cut: Management lowered Q2 and FY 2026 EPS and revenue guidance (Q2 EPS 0.82–0.84 vs. ~0.86 consensus; FY EPS 3.34–3.41 vs. ~3.45 consensus), trimming near‑term growth expectations and sparking profit‑forecast concern. Reuters: Cuts Forecast
• Negative Sentiment: Class‑action legal risk: Multiple law firms and investor alerts allege misstatements about electrophysiology demand during a defined class period — a wave of filings/solicitations raises litigation risk, potential distraction and possible future costs. PRNewswire: Investor Alert
• Negative Sentiment: Market sentiment/technical pressure: Shares hit a 52‑week low in the lead‑up to earnings as analysts trimmed forecasts — standing risk of continued downside if guidance disappointment persists. Blockonomi: 52‑Week Low

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Robert W. Baird decreased their target price on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a research note on Thursday. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. BTIG Research reduced their price objective on shares of Boston Scientific from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday. Barclays set a $96.00 target price on Boston Scientific and gave the stock an “overweight” rating in a research report on Thursday. Finally, Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $96.65.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently made changes to their positions in BSX. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the fourth quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the fourth quarter worth approximately $26,000. Sfam LLC acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $29,000. Finally, Pin Oak Investment Advisors Inc. bought a new stake in shares of Boston Scientific during the third quarter valued at approximately $41,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.